Use of the Multidimensional Haemophilia Pain Questionnaire (MHPQ) in Patients With Severe Haemophilia A Treated With Emicizumab: A Pilot Cross‐Sectional, Single‐Centre Study
Haemophilia · 2026-07 · 32 (4) · 1060-1066
DOI: 10.1111/hae.70318 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, online erschienen am 17.05.2026. Verfasst von Ilenia Lorenza Calcaterra und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine and Surgery, Regional Reference Centre For Coagulation Disorders, Federico II University, Naples, Italy. Hauptthemen laut MEDLINE: Hemophilia A, Antibodies, Monoclonal, Humanized, Antibodies, Bispecific, Pain. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Despite effective bleed prevention with Emicizumab, pain remains a relevant clinical burden in adults with severe haemophilia A (sHA). A multidimensional assessment is needed to better characterize contemporary haemophilia‐related pain.
Objective
To evaluate the prevalence, characteristics, and functional impact of pain in adults with sHA receiving Emicizumab prophylaxis using the Multidimensional Haemophilia Pain Questionnaire (MHPQ).
Methods
In this single‐centre, cross‐sectional pilot study, 27 adults with sHA on Emicizumab prophylaxis completed the MHPQ. Pain localization, frequency, triggering factors, intensity, and interference across life domains were assessed descriptively.
Results
Lifetime haemophilia‐related pain was reported by 85.2% of participants, and 77.8% experienced pain within the previous 12 months. Pain most frequently involved ankles (52.4%), knees (52.4%), and elbows (28.6%). All patients with recent pain reported pain during bleeding episodes; however, movement‐related triggers, including accidental movements (66.7%) and physical activity (54.2%), were also common. Pain intensity was generally mild‐to‐moderate, with the highest median scores observed after accidental movements (median 4, IQR 2–6). Pain interfered predominantly with general activity (71.4%), walking ability (66.7%), mood (61.9%), and enjoyment of life (61.9%). Arthropathy was documented in 70.4% of patients.
Conclusions
In the non‐factor prophylaxis era, pain remains prevalent and functionally relevant in adults with sHA despite effective bleed control. These findings suggest that haemophilia‐related pain is not exclusively bleeding‐driven and highlight the importance of structured, multidimensional pain assessment in routine haemophilia care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Medicine and Surgery, Regional Reference Centre For Coagulation Disorders, Federico II University, Naples, Italy.
Zitieren
APA
Calcaterra, I. L., Donnarumma, S., D'Errico, G., Luca, C., Caputo, C., Ciciola, P., Cimino, E., & Minno, M. D. (2026). Use of the Multidimensional Haemophilia Pain Questionnaire (MHPQ) in Patients With Severe Haemophilia A Treated With Emicizumab: A Pilot Cross‐Sectional, Single‐Centre Study. Haemophilia, 32(4), 1060-1066. https://doi.org/10.1111/hae.70318
Vancouver
Calcaterra IL, Donnarumma S, D'Errico G, Luca C, Caputo C, Ciciola P, et al. Use of the Multidimensional Haemophilia Pain Questionnaire (MHPQ) in Patients With Severe Haemophilia A Treated With Emicizumab: A Pilot Cross‐Sectional, Single‐Centre Study. Haemophilia. 2026;32(4):1060-1066. doi:10.1111/hae.70318
BibTeX
@article{Calcaterra2026,
author = {Calcaterra, Ilenia Lorenza and Donnarumma, Sofia and D'Errico, Guido and Luca, Carmine De and Caputo, Chiara and Ciciola, Paola and Cimino, Ernesto and Minno, Matteo Di},
title = {Use of the Multidimensional Haemophilia Pain Questionnaire (MHPQ) in Patients With Severe Haemophilia A Treated With Emicizumab: A Pilot Cross‐Sectional, Single‐Centre Study},
journal = {Haemophilia},
year = {2026},
volume = {32},
number = {4},
pages = {1060--1066},
doi = {10.1111/hae.70318}
}
EUVIMED